Contribute Try STAT+ Today

Top of the morning to you, and a fine one it is. Clear blue skies and deliciously cool breezes are wafting about the Pharmalot campus, where the official mascot is snoozing happily nearby and we are brewing yet another cup of stimulation. Our choice today is butter pecan, for those keeping track. Meanwhile, there is much to be done. The to-do list grows by the minute, it seems. Perhaps you can relate. On that note, here are a few items of interest to help you start your own journey. Hope all goes well today and, as always, do keep in touch. …

The U.S. Food and Drug Administration authorized a monoclonal antibody drug made by Vir Biotechnology (VIR) and GlaxoSmithKline (GSK) to treat early Covid-19 infections, The Wall Street Journal notes. The drug, called sotrovimab, is the third antibody medicine authorized to treat patients early in the course of disease who are at high risk of developing severe cases. Vir and Glaxo are betting the world will be fighting Covid-19 for years to come, even if at a much-reduced scale, because of new virus variants and uneven vaccination rates.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.